BerGenBio to Present at Upcoming Scientific Conferences

28 Mar 2023 08:00 CEST

- Data on AXL as a therapeutic target in lung cancers to be highlighted at AACR
-

- Ph1a/2b 1L STK11m NSCLC trial design to be outlined at ELCC -

BERGEN, Norway, March 28,2023 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical needs, today announced that the Company will be presenting
three posters at two upcoming scientific conferences: ESMO's European Lung
Cancer Congress (ELCC) 2023 and the American Association for Cancer Research
(AACR) Annual Meeting 2023.

European Lung Cancer Conference 2023

March 29 - April 1, 2023

Bella Center - Copenhagen, Denmark

Poster Title: Phase 1b/2a safety and tolerability study of bemcentinib with
pembrolizumab/carboplatin/pemetrexed in subjects with untreated advanced or
metastatic non-squamous NSCLC with/without STK11
mutations (https://cslide.ctimeetingtech.com/elcc23hybrid/attendee/confcal/prese
n
tation/list?q=78TiP)

Session Title: Poster Display session (ID 51)

Session Date & Time: Friday March 31, 2023, 12:00 PM - 12:45 PM

Location: Exhibition and Poster area

Presentation Number: 78TiP

American Association for Cancer Research Annual Meeting 2023

April 14 - 19, 2023

Orlando County Convention Center - Orlando, Florida

Poster Title:?AXL as a Therapeutic Target in STK11 mutant
NSCL (https://www.abstractsonline.com/pp8/#!/10828/presentation/3138)C
Session Title:?Combination Immunotherapies 1
Session Date and Time:?Monday Apr 17, 2023, 1:30 PM - 5:00 PM
Location:?Section 39
Poster Board Number:?18
Abstract Presentation Number:?3245

Poster Title:? Combined inhibition of AXL and ATR enhances replication stress,
cell death and immune response in small cell lung
cancer (https://www.abstractsonline.com/pp8/#!/10828/presentation/1853)
Session Title:? DNA Repair / Molecular Classification of Tumors for Diagnostics,
Prognostics, and Therapeutic Outcomes
Session Date and Time:?Wednesday Apr 19, 2023, 9:00 AM - 12:30 PM
Location:?Section 18
Poster Board Number:?8
Abstract Presentation Number:?6206

The posters from both conferences will be available on the Company's website in
the Scientific
Presentations (https://www.bergenbio.com/investors/presentations/) portion of
the Investors section following their presentations.

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

graham.morrell@bergenbio.com

Media Relations Norway

Jan Lilleby

jl@lillebyfrisch.no

+47 90 55 16 98

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site